Being a Life Sciences Leader

Bill Sibold, Madrigal Pharmaceuticals

Life Sciences Pennsylvania Season 7 Episode 10

Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.